Ocean Biomedical awarded multiple patents for CHI3L1 antibody cancer therapies; deal with Aesther SPAC pending

Ocean Biomedical, Inc.

Dr. Jack A. Elias granted patents for mono-specific and bispecific antibodies targeting CHI3L1 to suppress multiple cancers.
Antibodies cover CHI3L1 alone, CHI3L1/PD-1 bispecific, and CHI3L1/CTLA4 bispecific.
Technology described as 'master regulator' of immune checkpoint pathways; shown to control lung cancer in murine models.
Ocean Biomedical expected to list on Nasdaq under OCEA/OCEAW after business combination with Aesther (AEHA).
Patents cover prostate, colon, ovarian, breast, lung cancers, glioblastoma, melanoma, etc.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.